Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTX NASDAQ:EPIX NASDAQ:EXOZ NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$2.05+0.5%$1.96$1.41▼$2.79$92.72M1.4667,158 shs44,516 shsEPIXESSA Pharma$1.88+0.5%$1.72$1.40▼$7.88$83.01M1.56369,136 shs328,689 shsEXOZeXoZymes$9.25$12.16$8.50▼$23.99$77.40MN/A11,602 shs1,872 shsRLMDRelmada Therapeutics$0.58-3.0%$0.64$0.24▼$4.37$19.75M0.59971,973 shs214,781 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+0.49%+18.50%+3.02%+14.53%+8.47%EPIXESSA Pharma+0.53%+9.94%+11.24%+5.03%-67.02%EXOZeXoZymes0.00%-5.71%-25.10%-14.67%+924,999,900.00%RLMDRelmada Therapeutics-3.04%-5.41%-17.56%+99.10%-84.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio2.1715 of 5 stars3.55.00.00.00.60.80.0EPIXESSA Pharma1.0193 of 5 stars1.02.00.00.02.32.51.3EXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/ARLMDRelmada Therapeutics4.6638 of 5 stars3.15.00.04.41.14.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 3.00Buy$10.00387.80% UpsideEPIXESSA Pharma 2.00Hold$2.006.38% UpsideEXOZeXoZymes 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.25Hold$5.00766.55% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$223K417.83N/AN/A$0.23 per share8.91EPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AEXOZeXoZymesN/AN/AN/AN/A$1.25 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/AN/AN/AN/ARLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)Latest RLMD, EPIX, EXOZ, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ENTXEntera Bio-$0.11N/AN/AN/AN/AN/A8/6/2025Q2 2025RLMDRelmada Therapeutics-$0.25N/AN/AN/AN/AN/A8/4/2025Q3 2025EPIXESSA Pharma-$0.2430N/AN/AN/AN/AN/A5/12/2025Q1 2025EXOZeXoZymesN/A-$0.22N/A-$0.22N/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/A5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 million5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A13.0713.07EPIXESSA PharmaN/A67.1567.15EXOZeXoZymesN/A6.526.52RLMDRelmada TherapeuticsN/A5.295.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%EPIXESSA Pharma75.12%EXOZeXoZymesN/ARLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.38%EPIXESSA Pharma15.50%EXOZeXoZymes72.41%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2045.45 million40.73 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableEXOZeXoZymes298.37 million2.31 millionN/ARLMDRelmada Therapeutics1033.19 million26.32 millionOptionableRLMD, EPIX, EXOZ, and ENTX HeadlinesRecent News About These CompaniesRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | finance.yahoo.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | globenewswire.comRelmada terminates license agreement for troubled phase 3 depression assetJuly 11, 2025 | fiercebiotech.comFDIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of DirectorsJuly 9, 2025 | globenewswire.comRelmada Therapeutics Inc News (RLMD) - Investing.comJuly 2, 2025 | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder CancerJune 17, 2025 | quiverquant.comQRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-UrologyJune 17, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in StockMay 21, 2025 | insidertrades.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 8, 2025 | globenewswire.comRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28, 2025 | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28, 2025 | globenewswire.comRelmada Therapeutics to hold a virtual meetingApril 27, 2025 | markets.businessinsider.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLMD, EPIX, EXOZ, and ENTX Company DescriptionsEntera Bio NASDAQ:ENTX$2.05 +0.01 (+0.49%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.09 +0.04 (+2.15%) As of 07/18/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.ESSA Pharma NASDAQ:EPIX$1.88 +0.01 (+0.53%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.87 -0.01 (-0.53%) As of 07/18/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.eXoZymes NASDAQ:EXOZ$9.25 0.00 (0.00%) As of 07/18/2025 10:13 AM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Relmada Therapeutics NASDAQ:RLMD$0.58 -0.02 (-3.04%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.57 0.00 (-0.69%) As of 07/18/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.